李文东
美沙拉嗪与柳氮磺吡啶治疗溃疡性结肠炎的对比研究
李文东
【摘要】目的 对比溃疡性结肠炎患者采用美沙拉嗪和柳氮磺砒啶治疗的疗效。方法 选取2014年11月~2015年11月收治的81例溃疡性结肠炎患者进行治疗研究,随机分组,实验组44例患者采用美沙拉嗪的治疗,对照组37例患者采用柳氮磺吡啶治疗,比较两组患者的治疗效果。结果 实验组治疗有效率为93.18%,对照组治疗有效率为83.78%,实验组患者的治疗效果更加显著(P<0.05)。实验组不良反应率为4.5%,对照组不良反应率为18.9%。对照组患者不良反应率高于对照组(P<0.05)。结论 溃疡性结肠炎患者采用美沙拉嗪治疗,效果更加显著,而且不良反应少。
【关键词】溃疡性结肠炎;美沙拉嗪;柳氮磺吡啶
Objective To compare the curative effect of Mesalazine and Sulfasalazine in the treatment of ulcerative colitis. Methods From November 2014 to November 2015,81 cases of patients with ulcerative colitis who are treated in hospital were selected and were dividedinto two group at random;44 patients in study group were given about Mesalazine medication treatment,while another 37 patients in control group were given about Sulfasalazine medication treatment and then to compare the curative effects between two groups. Results The effective rate of study group was 93.18%,which was higher than 83.78% in control group,the difference was statistically significant (P<0.05);Besides,the incidence rate of adverse reactions in study group was 4.5%,which was lower than 18.9% in control group (P<0.05). Conclusion The application of Mesalazine in the treatment of ulcerative colitis has significant effects and has advantage of the low incidence rate of adverse reactions.
【Key words】Ulcerative colitis,Mesalazine,Sulfasalazine
溃疡性结肠炎为非特异性炎症性肠病,病因不明确,病变部位一般在直肠和乙状结肠,还可衍生到降结肠,严重者会累及整个结肠。患者会有黏液脓血便、腹泻和腹痛的症状,为慢性疾病,病程长,而且反复发作[1]。在临床治疗中一般选择柳氮磺吡啶这种药物,口服后只有部分在胃肠道进行吸收,有将近30%患者治疗后出现呕吐、恶心、厌食等不良反应,而停止治疗[2]。最近在不断的临床研究中,发现美沙拉嗪也可使患者得到显著的疗效,而且不良反应少,安全性高[3]。本次选取2014年11月~2015年11月收治的81例溃疡性结肠炎患者进行治疗研究,观察患者的治疗效果,现报告如下。
1.1一般资料
选取2014年11月~2015年11月收治的81例溃疡性结肠炎患者进行治疗研究,实验组患者44例,男性25例,女性19例,年龄22~73岁,平均年龄(43±1.6)岁,病程范围2个月~9.5年,平均病程(4.0±1.2)年,24例为中度,20例为轻度。……